跳至主要内容
临床试验/NCT05832398
NCT05832398招募中不适用

Precision Chemotherapy Based on Organoid for Colorectal CancerPatient-Derived Tumor Organoid Drug Sensitivity for Colorectal Cancer: A Prospective, Multicentre,Randomized, Controlled Trial

Nanfang Hospital, Southern Medical University1 个研究点 分布在 1 个国家目标入组 186 人开始时间: 2023年5月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
186
试验地点
1
主要终点
1. Progression-free survival

研究概览

简要总结

The purpose of this study is to investigate whether chemotherapy guided by patient-derived tumor organoid drug test can improve the outcomes of stage IV colorectal cancer.

详细描述

Fluorouracil-based chemotherapy is the standard treatment for stage IV colorectal cancer patients. However, the effects of chemotherapy remains limited. Patient-derived tumor organoids are increasingly used as tools for drug test and predicting drug response in the clinic, and have been showed to faithfully predict clinical outcomes of patients with CRC. A prospective clinical trial is needed to validate whether the in vitro sensitivity to chemotherapy regimens in organoids drug test is associated with a longer PFS in stage IV colorectal cancer.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age between 18 and 70
  • Histological confirmed colorectal cancer
  • American Society of Anesthesiologists (ASA) score I~III
  • No contraindication for chemotherapy
  • No evidence of other malignant tumor

排除标准

  • Refusing chemotherapy
  • Pregnant or breast-feeding women
  • Severe organ damage after chemotherapy, surgery or unable to continue to systemic chemotherapy

研究组 & 干预措施

Organoid guided chemotherapy

Experimental

Patients will receive sensitive chemotherapy in organoid drug test once every two weeks for 6 cycles as adjuvant chemotherapy

干预措施: FOLFOX , FOLFIRI or FOLFOXIRI regimens (Drug)

FOLFOX regimen

Active Comparator

Patients will receive FOLFOX regimen once every two weeks for 6 cycles as adjuvant chemotherapy

干预措施: FOLFOX or CapeOX regimens (Drug)

结局指标

主要结局

1. Progression-free survival

时间窗: up to 1 years

the time from randomization to relapse or death, whichever occurred first

次要结局

  • Overall survival(up to 5 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验